Pazopanib Included in NCCN Oncology Guidelines

3 November 2009 (Last Updated November 3rd, 2009 18:30)

The National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines in oncology for kidney cancer to include pazopanib as a therapy option for patients in the advanced stages of the illness. The Food and Drug Administration (FDA) approved pazopanib on 19 Octob

The National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines in oncology for kidney cancer to include pazopanib as a therapy option for patients in the advanced stages of the illness.

The Food and Drug Administration (FDA) approved pazopanib on 19 October for advanced renal cell carcinoma, in which cancerous cells invade the lining of small tubes in the kidney called tubules.

The NCCN guidelines panel for kidney cancer has added pazopanib as a first-line therapy option for certain categories of patients, and it has been added into the options for subsequent therapy for those with predominant clear cell histology following cytokine therapy.

A number of kidney cancer therapies have recently been approved by the US FDA including everolimus, which was included in the NCCN guidelines earlier in the year.